|
25th June 2007 (Day I -
Monday) |
|
8.30 – 9.30 AM |
Registration
|
|
|
Session I – Key note Address and Inauguration |
|
9.30 AM |
Welcome |
Dr S.K.Maulik |
|
9.35 AM |
Introduction to Workshop |
Prof Y.K.Gupta |
|
9.45 AM |
Dean’s Remark |
Prof T.D.Dogra |
|
9.55 AM |
Dean’s Remark |
Prof R.C. Deka |
|
10.05 AM |
Keynote Address |
Dr M.Venkateswarlu |
|
10.20 AM |
Inaugural Address |
Dr R.K.Srivastava |
|
10.40 AM |
Presidential Address |
Prof. N.K. Ganguly |
|
11.00 AM |
Vote of Thanks |
Dr Jagriti Bhatia |
| |
Tea |
|
|
Session II – Workshop Sensitization Session |
|
11.15 AM |
Issues with FDC use in India |
Dr. Y.K.Gupta |
|
FDC: Perspectives of the Stakeholders |
|
11.30 AM |
Clinical Pharmacologist’s View |
Dr. M.U.R. Naidu |
|
11.45 AM |
Clinicians’ Consideration |
Dr Anoop Mishra |
|
12.00 PM |
Industry’s Angle |
Dr Shoibal Mukherjee |
|
12.15 PM |
Discussion |
|
|
1.00 PM |
Lunch |
|
|
Session III – Important FDC issues |
|
2.00 PM |
How does FDC affect Pharmacoeconomics? Dr. Uma Tekur |
|
2.10 PM |
FDC and patient compliance:
Perceptions and Evidence |
Dr P. Aggarwal |
|
2.20 PM |
FDC use and
drug resistance |
Dr K.K. Sharma |
|
2.30 PM |
Pharmacovigilance aspect of FDC usage |
Dr S.K.Tripathi |
|
2.40 PM |
Discussion |
|
| |
Tea |
|
|
Session IV – Criteria for assessment of safety of FDC |
|
3.45 PM |
Trigger Talk |
Dr Y.K.Gupta |
|
4.00 PM |
Panel
Discussion and Guideline Framing |
|
|
5.00 PM |
Disperse |
|
|
7.00 PM |
Round Table
Dinner Discussion |
|
| |
|
|
|
26th June 2007 (Day II –
Tuesday) |
| |
Session V |
|
|
9.30 AM |
Recap of day
I |
|
|
Session VI – Panel discussion (at 4 Different Venues) |
|
10.00 AM |
Panel 1: FDC of antimicrobials as antidiarrhoeal
preparations |
| |
Panel 2: FDC of α blockers, 5α reductase inhibitors
and antimuscarinics
for treatment of benign prostatic hyperplasia |
| |
Panel 3: FDC of COX inhibitors, analgesics, muscle
relaxants and
proteolytic enzymes for inflammation and pain |
| |
Panel 4: FDC of proton pump inhibitors, H2 blocker,
antiemetics and
gastrokinetics for acid peptic disease |
|
11.15 AM |
Tea |
|
Session VII – Panel Discussion (at 4 Different Venues) |
|
11.30 AM |
Panel 5: FDC of antibiotics, analgesics,
antitussives and mucolytics for
respiratory infections |
| |
Panel 6: FDC of β agonists and corticosteroids for
asthma |
| |
Panel 7: FDC used in the treatment of hypertension |
| |
Panel 8: FDC of antiepleptic and antimigrane drugs |
|
12.45 PM |
Lunch |
|
Session VIII |
|
1.30 PM |
Presentation by rapporteur of Session VI |
|
1.50 PM |
Presentation by rapporteur of Session VII |
|
2.10 PM |
Discussion on Reports |
|
3.00 PM |
Preparation of guidelines for FDC |
|
4.00 PM |
Valedictory Function |
|
4.15 PM |
Tea |
| |
|
Note for Panel Discussion
-
Composition
of Panels: Each panel will have representation from
-
Regulators
-
Pharmaceutical industries
-
Clinicians
-
Pharmacologists
-
The Panelists
will opt for one panel in Session VI and one in Session
VII depending on the choice
and expertise.
-
The
rapporteurs of each panel will present the proceedings
in the next session
|
